Literature DB >> 33432947

Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis via activating the PI3K/Akt pathway and suppressing the FoxO1 pathway in type 2 diabetes.

Xiaoya Sun1, Ziqiang Cao1, Yuanyuan Ma2, Yimin Shao1, Junqing Zhang1, Geheng Yuan1, Xiaohui Guo1.   

Abstract

Dapagliflozin alleviates hyperglycemia by increasing glycosuria, but it induces renal gluconeogenesis, thus neutralizing its efficacy. Resveratrol (Rsv), a natural polyphenolic chemical, improves insulin sensitivity in type 2 diabetes (T2D). Here, we investigated the regulatory effects and underlying mechanisms of Rsv on dapagliflozin-induced renal gluconeogenesis. Male ob/ob mice were given the vehicle (HF), dapagliflozin (1 mg kg-1), Rsv (10 mg kg-1), or dapagliflozin and Rsv combination for 10 weeks. Glucose metabolism was evaluated by glucose and pyruvate tolerance tests. HK-2 cells (human renal proximal tubule cells) were treated with dapagliflozin (1 μmol L-1) for 2 h and further incubated with Rsv (10 μmol L-1) for 12 h. The effects of Rsv on gluconeogenesis and insulin signaling were assessed. Dapagliflozin treatment increased glucose production in HK-2 cells and lowered blood glucose and induced gluconeogenesis in ob/ob mice. After Rsv treatment, the enhanced glucose production and gluconeogenesis were alleviated. The upregulated mRNA and protein expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) and the activation of the forkhead transcription factor O1 (FoxO1) protein in the dapagliflozin group were attenuated by Rsv administration. Rsv also improved renal insulin signaling by increasing PI3K and Akt phosphorylation. The PI3K inhibitor LY294002 dramatically decreased the p-Akt expression and activated FoxO1 by dephosphorylation, thus diminishing the inhibitory effects of Rsv on dapagliflozin-induced PEPCK and G6Pase expression. The data showed the mechanisms of Rsv in attenuating dapagliflozin-induced renal gluconeogenesis via activating the PI3K/Akt pathway and further suppressing FoxO1 activation, suggesting a potential intervention to achieve better glucose-lowering effects for SGLT2 inhibitors in T2D therapy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33432947     DOI: 10.1039/d0fo02387f

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  5 in total

Review 1.  The sugar daddy: the role of the renal proximal tubule in glucose homeostasis.

Authors:  Zahraa S Hotait; Julia N Lo Cascio; Elijah N D Choos; Blythe D Shepard
Journal:  Am J Physiol Cell Physiol       Date:  2022-08-01       Impact factor: 5.282

2.  Blocking of SGLT2 to Eliminate NADPH-Induced Oxidative Stress in Lenses of Animals with Fructose-Induced Diabetes Mellitus.

Authors:  Ying-Ying Chen; Tsung-Tien Wu; Chiu-Yi Ho; Tung-Chen Yeh; Gwo-Ching Sun; Ching-Jiunn Tseng; Pei-Wen Cheng
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

3.  Dapagliflozin attenuates cholesterol overloading-induced injury in mice hepatocytes with type 2 diabetes mellitus (T2DM) via eliminating oxidative damages.

Authors:  Liu Yang; Dan Liu; Hongqin Yan; Kaixia Chen
Journal:  Cell Cycle       Date:  2022-01-31       Impact factor: 4.534

Review 4.  Exosomes as Promising Nanostructures in Diabetes Mellitus: From Insulin Sensitivity to Ameliorating Diabetic Complications.

Authors:  Milad Ashrafizadeh; Alan Prem Kumar; Amir Reza Aref; Ali Zarrabi; Ebrahim Mostafavi
Journal:  Int J Nanomedicine       Date:  2022-03-19

Review 5.  Resveratrol in Treating Diabetes and Its Cardiovascular Complications: A Review of Its Mechanisms of Action.

Authors:  Meiming Su; Wenqi Zhao; Suowen Xu; Jianping Weng
Journal:  Antioxidants (Basel)       Date:  2022-05-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.